First experiences with esketamine nasal spray in patients with moderate and severe treatment-resistant depression

Q4 Medicine

Psiquiatria Biologica Pub Date : 2024-11-23 DOI:10.1016/j.psiq.2024.100547

José Miguel Meca García, María Teresa Perní Lasala, María Beret Trancón, Ricardo Jesús Lara Mellado, Antonio José Ureña Caballero, Raquel Fernández Villalobos, José Enrique Romero Baca

{"title":"First experiences with esketamine nasal spray in patients with moderate and severe treatment-resistant depression","authors":"José Miguel Meca García, María Teresa Perní Lasala, María Beret Trancón, Ricardo Jesús Lara Mellado, Antonio José Ureña Caballero, Raquel Fernández Villalobos, José Enrique Romero Baca","doi":"10.1016/j.psiq.2024.100547","DOIUrl":null,"url":null,"abstract":"<div><div>We report 4 cases of female patients with treatment-resistant depression treated with intranasal esketamine. The age of 2 patients were over 50, with only 1 patient in their 20s. The time course of the disease episode ranged from 2 to 4 years, 2 of the cases had psychiatric comorbidity, the time of administration in the patients who completed treatment ranged from 31 to 41 weeks with a discontinuation of treatment due to non-serious but intolerable side effects for one of the patients at 12 weeks. Oral treatment was not substantially modified, with the only notable change being the almost complete withdrawal of benzodiazepines in some cases. The results were satisfactory, with clinical improvement evident in the clinical assessment and in the scales, with 2 patients in complete remission and another in partial remission. Two of these patients returned to work.</div></div>","PeriodicalId":39337,"journal":{"name":"Psiquiatria Biologica","volume":"32 2","pages":"Article 100547"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psiquiatria Biologica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1134593424001076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

We report 4 cases of female patients with treatment-resistant depression treated with intranasal esketamine. The age of 2 patients were over 50, with only 1 patient in their 20s. The time course of the disease episode ranged from 2 to 4 years, 2 of the cases had psychiatric comorbidity, the time of administration in the patients who completed treatment ranged from 31 to 41 weeks with a discontinuation of treatment due to non-serious but intolerable side effects for one of the patients at 12 weeks. Oral treatment was not substantially modified, with the only notable change being the almost complete withdrawal of benzodiazepines in some cases. The results were satisfactory, with clinical improvement evident in the clinical assessment and in the scales, with 2 patients in complete remission and another in partial remission. Two of these patients returned to work.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Psiquiatria Biologica Medicine-Psychiatry and Mental Health

CiteScore

0.40

自引率

0.00%

发文量

期刊介绍： Es la Publicación Oficial de la Sociedad Española de Psiquiatría Biológica. Los recientes avances en el conocimiento de la bioquímica y de la fisiología cerebrales y el progreso en general en el campo de las neurociencias han abierto el camino al desarrollo de la psiquiatría biológica, fundada sobre bases anatomofisiológicas, más sólidas y científicas que la psiquiatría tradicional.